- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
Clinicaltrials.gov identifier NCT03942263
Recruitment Status Active, not recruiting
First Posted May 8, 2019
Last update posted February 24, 2021
The purpose of this study is to describe patterns of treatment used for cHL and sALCL in real world setting.
This is a non-interventional, prospective and retrospective study of participants with cHL and sALCL. The study will collect information on therapy and outcome of cHL and sALCL in real-life clinical practice. The study will enroll approximately 2000 participants. Based on the diagnosis of the disease, participants will be assigned to one of the following groups: - Newly Diagnosed and RR cHL Participants - Newly Diagnosed and RR sALCL Participants This multi-center trial will be conducted in Russia. The retrospective data will be collected for the participants with RR cHL or RR sALCL at the time of enrollment and for participants with RR cHL or RR sALCL within 3 years prior to inclusion in the study at Visit 1 (Baseline). The prospective data will be collected for a period of 2 years from Visit 1 (Baseline) to Visit 5 (Month 24, Final Visit), both for newly diagnosed participants with cHL or sALCL and participants with RR cHL or RR sALCL at the time of enrolment, and participants with RR cHL or RR sALCL within 3 years prior to inclusion in the study.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, , Learn About Clinical Studies.-->
1. Male and female participants 18 years or older by the time of enrollment.
2. Histologically confirmed diagnosis of cHL or sALCL.
3. Newly diagnosed participants, or participants with RR cHL or RR sALCL at the time of
enrollment, or participants with RR cHL or RR sALCL within 3 years prior to inclusion
in the Study.
1. Unconfirmed diagnosis of cHL or sALCL.
2. Current, previous (within the last 3 years) or planned (for the next 2 years)
participation in interventional clinical trials.
3. Participation in the non-interventional study CHL-5001 "An international,
multi-centre, non-interventional retrospective study to describe treatment pathways,
outcomes, and resource use in participants with classical Hodgkin lymphoma
(B-HOLISTIC)" (Sponsor is Takeda Pharmaceuticals International AG).
4. Participants for whom the minimum study dataset was not available from their hospital
State budgetary healthcare institution of the Astrakhan region Alexander-Mariinsky regional clinical hospital
State budgetary health care institution "Chelyabinsk Regional Clinical Center for Oncology and Nuclear Medicine"
State Budget Public Health Institution "Regional Oncological Dispensary", Irkutsk
Kaluga Regional Clinical Oncologic Dispensary
Tatarstan Regional Clinical Cancer Center
Regional State Budgetary Institution of Health "Regional Clinical Hospital 1" named after Professor S.I. Sergeeva, Ministry of Health of the Khabarovsk Territory
Regional State Budgetary Institution of Healthcare Krasnoyarsk Regional Clinical Oncologic Dispensary named after A.I. Kryzhanovsky"
Federal State Budgetary Institution "National Medical-Surgical Center named after N.I. Pirogov" Ministry of Health of the Russian Federation
The Moscow State Clinical Hospital No. 52 of the Moscow City Department of Healthcare, State Budgetary Institution of Health Care
Federal State Budgetary Educational Institution of Higher Education Rostov State Medical University of the Ministry of Health of the Russian Federation
State Budgetary Institution of Healthcare Leningrad Regional Clinical Hospital
State Healthcare Institution of Tula Region "Tula Regional Clinical Hospital"
State autonomous health care institution of the Tyumen region "Multidisciplinary clinical medical center "Medical City"
Ministry of Health of the Republic of Bashkortostan State Autonomous Healthcare Institution Republican Clinical Oncologic Dispensary
State budgetary health care institution "Volgograd Regional Clinical Oncology Center"
Study Director: Medical Director Takeda